aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Selecta Biosciences is a biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for treating and preventing human diseases. Founded in 2008 and headquartered in Watertown, Massachusetts, the company leverages its proprietary product platform technology, which combines advanced immunobiology with nanotechnology to create targeted immunomodulatory nanoparticles.
The company's innovative approach aims to address unmet medical needs by harnessing the power of nanoparticle-based therapies. Selecta Biosciences' work represents a significant step forward in the field of immunotherapy, potentially offering new treatment options for various diseases and contributing to the advancement of precision medicine.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Immunomodulatory Drugs
Technology
Biotech, Nanotechnology
Model Types
Platform
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Selecta Biosciences founded?
Selecta Biosciences was founded in 2008.
Where is Selecta Biosciences’s headquarters located?
Selecta Biosciences’s headquarters is located in Watertown, MA, US.
When was Selecta Biosciences’s last funding round?
Selecta Biosciences’s most recent funding round was for $60.3M (USD) in November 2023.
How many employees does Selecta Biosciences have?
Selecta Biosciences has 75 employees as of Feb 4, 2024.
How much has Selecta Biosciences raised to-date?
As of July 05, 2023, Selecta Biosciences has raised a total of $380.5M (USD) since Nov 13, 2023.
Add Comparison
Total Raised to Date
$380.5M
USD
Last Update Nov 13, 2023
Last Deal Details
$60.3M
USD
Nov 13, 2023
Post Ipo Equity
Total Employees Over Time
75
As of Feb 2024
Selecta Biosciences Address
480 Arsenal St
Watertown,
Massachusetts
02472
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts